

Date: 03/11/2021

From: [REDACTED]

To [REDACTED]

cc

bcc

Subject MHRA Ref: [REDACTED]

Dear [REDACTED],

Regarding the FSN/FSCA we have still not received a response to the most recent email.

Please can you provide the requested further information and update outlined in the email below by **Friday 5th November**.

Kind regards

[REDACTED]  
Higher Medical Device Specialist  
Medical Devices - Safety & Surveillance

Medicines and Healthcare products Regulatory Agency  
10 South Colonnade, Canary Wharf, London E14 4PU  
Direct line: [REDACTED]  
[REDACTED]

[gov.uk/mhra](https://gov.uk/mhra)  
Stay connected

[Register your medical devices with MHRA](#)

[Read our guidance on coronavirus \(COVID-19\)](#)

MHRA launched a public consultation on future UK medical device regulations on 16 September 2021, which will close on 25 November 2021. [Find out more here](#). The consultation documents can be found [here](#).

Date: 12/10/2021

From: [REDACTED]

To [REDACTED]

cc [REDACTED]

bcc

Subject [REDACTED] SCA First Reminder MHRA Ref: [REDACTED]

Dear [REDACTED],

Thank you for the previous update.

Please could you provide an update of the number of total acknowledgements to date.

I have also received an email from Great Ormond Street Hospital regarding this FSN enquiring as to why they did not didn,t receive the alert from the manufacturer and patients were treated with faulty batches after the alert was issued. Please can you clarify as to why this hospital was not included in your customer list and did not receive the FSN?

I look forward yo your response by **Tuesday 19<sup>th</sup> October**.

[REDACTED]  
Higher Medical Device Specialist  
Medical Devices - Safety & Surveillance

Medicines and Healthcare products Regulatory Agency  
10 South Colonnade, Canary Wharf, London E14 4PU  
Direct line: [REDACTED]  
[REDACTED]

[gov.uk/mhra](https://gov.uk/mhra)  
Stay connected

[Register your medical devices with MHRA](#)

[Read our guidance on coronavirus \(COVID-19\)](#)

**MHRA launched a public consultation on future UK medical device regulations on 16 September 2021, which will close on 25 November 2021. [Find out more here](#). The consultation documents can be found [here](#).**

**Date:** 02/07/2021

**From:** [REDACTED]

**To:** [REDACTED] AIC  
<AIC@mhra.gov.uk>  
**cc:** [REDACTED]  
**bcc:**

**Subject:** [REDACTED] First Reminder MHRA Ref:

**Attachments:** <<see below >>

-----Original Message-----

**From:** [REDACTED]  
**Sent:** 02 July 2021 13:13  
**To:** [REDACTED]; AIC <AIC@mhra.gov.uk>  
**Cc:** [REDACTED]  
**Subject:** UPDATE : FSN/FSCA First Reminder MHRA Ref: [REDACTED]

Good Afternoon [REDACTED],

I am just providing you with an update in regards to the Histoacryl Recall.

The Reconciliation attached is for the first 2 updates to this recall. We are currently awaiting acknowledgements from 7 customers on this.

The Reconciliation 22.04.2021 attached is for the third update to the recall. On this one we are currently awaiting 48 acknowledgements.

For both of these all customers have been chased today and have been given a deadline of the 16th July 2021 to respond to us. This is the fourth chase that has been completed for the recall.

We will provide you another update following the deadline of this chase.

Kind Regards

[REDACTED]

[REDACTED]

Quality Department

Tel: [REDACTED]

Email: [REDACTED]

Please note my normal working days are Thursday & Friday

B|BRAUN

B. Braun Medical Ltd, Brookdale Road, Sheffield, S35 2PW.

-----Original Message-----

From: [REDACTED]

Sent: 04 May 2021 15:34

To: [REDACTED]

Cc: aic@mhra.gov.uk

Subject: FW: FSN/FSCA First Reminder MHRA Ref: [REDACTED]

Dear [REDACTED],

Please see attached the updated risk assessment. An update for the corrective action is as follows:

Corrective Actions / Activities Update:

Currently, the investigation is focused in determining the fine tuning adjustment of the S02 concentration in the raw material, a task made in collaboration with the supplier that is performing their own investigation. On the other hand, the optimal transport and storage conditions are being evaluated in order to assess the influence in the S02 equilibrium to avoid the modification of the usual polymerization profile.

Attached is a copy of the acknowledgements we have received to date.

We have provided a further update with additional batches at the end of April. We have therefore also attached for your information the list of acknowledgements that we have received to date from this additional update on the 22.04.2021.

Kind Regards

[REDACTED]

[REDACTED]

Quality Department

Tel: [REDACTED]

Email: [REDACTED]

Please note my normal working days are Thursday & Friday

B|BRAUN

B. Braun Medical Ltd, Brookdale Road, Sheffield, S35 2PW.

We believe in improving people,s health through everything we do.

Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive. B. Braun is one of the world,s

leading manufacturers of medical devices, pharmaceutical products and services.  
B. Braun - Sharing Expertise

-----Original Message-----

From: [REDACTED]  
Sent: 22 April 2021 09:41  
To: [REDACTED]  
Subject: FSN/FSCA First Reminder MHRA Ref: [REDACTED]

22/04/2021

MHRA ref: [REDACTED] quote this in any reply

Your ref: [REDACTED]

To date we have not received your final report.

Why we're writing to you now

We need an update on acknowledgements and progress on any corrective action.

If you haven't already done so, please provide the information requested in our last email.

What you need to do now

Send us the information within 10 days of this email so we can decide whether to take further action.

You don't need to re-send copies of correspondence you have sent us previously.

Yours sincerely  
Adverse Incidents & Communications Team  
MHRA, Devices

Note

Use this email address [aic@mhra.gov.uk](mailto:aic@mhra.gov.uk) to contact us. We check it regularly.

You can access the Medical Device Safety Officer (MDSO) contact list via the Manufacturer Online Reporting Environment (MORE) in order to copy them in on communications regarding Field Safety Notices (FSNs). This can help you ensure appropriate targeting and prompt action of the FSN within the MDSO's organisation.

---

This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful.

If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications.

For more information on the Department of Health's email policy, click

[DHTermsAndConditions](#)

The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of the company of the sender of this e-mail. Unauthorized use, disclosure, or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail and destroy this communication and all copies thereof, including all attachments.

[attachment "Reconciliation.xlsx" deleted by [REDACTED]/MHRA] [attachment "Reconciliation 22.04.2021.xlsx" deleted by [REDACTED]/MHRA]